Locus Biosciences—a clinical-stage biotech developing a new class of CRISPR-based antibacterial drugs—just closed a $35 million financing round with backing from Johnson & Johnson. The $35 million ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback